Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.

France’s Servier bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios Pharmaceuticals in a deal worth up to $2 billion.

AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.

If all things go well, the Pfizer-BioNTech Covid-19 vaccine will receive EUA from the U.S. Food and Drug Administration around December 10 or within a few days after, and the Moderna vaccine will receive EUA around December 17 or within a few days after.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.

Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.

Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.

San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.

A new $1 billion fund backed by 20 drugmakers including Merck & Co. Inc. and Pfizer Inc. is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.